Fundz

Sudo Biosciences reported raising $53.3 Million in an initial SEC Form D filing, from an offering of $141 Million

PRIVATEDec 28, 2023

Amount Raised

$53.3 Million

$53.3 Million sold, per SEC Form D (first sale Dec 15, 2023)

Round Type

Venture

CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology Research

Who to call at Sudo Biosciences, and when

A new round usually means Sudo Biosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Sudo Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Sudo Biosciences, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Sudo Biosciences

Location

Carmel, Indiana, United States

About

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases. Its pipeline includes a potential first- and best-in-class, once-daily oral, brain-penetrant candidate for multiple sclerosis and other neuroinflammatory conditions, as well as a topical candidate for dermatologic diseases. Based in Carmel, IN and London, U.K., Sudo is advancing novel medicines designed to improve patient lives.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Sudo Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Sudo Biosciences's next move

See what Strategic adds

Sudo Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.